PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ibrutinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

22 hits

Bibliografisk träff 2013-12-05

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2013-07-515361

Bibliografisk träff 2013-12-04

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2013-06-511154

Bibliografisk träff 2013-11-25

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.

Leukemia · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1038/leu.2013.358

Bibliografisk träff 2013-10-02

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Molica S.

Expert Rev Hematol · comment; journal article · DOI 10.1586/17474086.2013.831324

Bibliografisk träff 2013-10-01

[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].

Deng Y, Tao SD, Zhang X, He ZM, Chen Y, Deng ZK, Li YY, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · research support, non-u.s. gov't; journal article · DOI 10.7534/j.issn.1009-2137.2013.05.018

Bibliografisk träff 2013-09-24

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.

Aalipour A, Advani RH.

Br J Haematol · research-article; review; journal article · DOI 10.1111/bjh.12573

Bibliografisk träff 2013-08-28

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

Burger JA, Buggy JJ.

Leuk Lymphoma · research support, non-u.s. gov't; review; journal article · DOI 10.3109/10428194.2013.777837

Bibliografisk träff 2013-08-19

Ibrutinib and novel BTK inhibitors in clinical development.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1186/1756-8722-6-59

Bibliografisk träff 2013-08-17

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.

Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S.

Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2013.07.028

Bibliografisk träff 2013-08-12

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L.

Blood · research support, n.i.h., intramural; clinical trial; research-article; journal article · DOI 10.1182/blood-2013-02-482125

Bibliografisk träff 2013-08-01

Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.

Vargas L, Hamasy A, Nore BF, Smith CI.

Scand J Immunol · research support, non-u.s. gov't; review; journal article · DOI 10.1111/sji.12069

Bibliografisk träff 2013-08-01

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

Jain N, O'Brien S.

Hematol Oncol Clin North Am · research-article; review; journal article · DOI 10.1016/j.hoc.2013.01.006

Bibliografisk träff 2013-07-25

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC.

Blood · clinical trial; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2013-06-507947

Bibliografisk träff 2013-06-24

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Brown JR.

Leuk Lymphoma · research support, non-u.s. gov't; review; journal article · DOI 10.3109/10428194.2013.803226

Bibliografisk träff 2013-06-19

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1215637

Bibliografisk träff 2013-05-16

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.

Chavez JC, Sahakian E, Pinilla-Ibarz J.

Core Evid · review-article; journal article · DOI 10.2147/ce.s34068

Bibliografisk träff 2013-04-26

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.

Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, Liu D, Keyvanfar K, Chapman CM, Chen J, Buggy JJ, Aue G, Tisdale JF, Pérez-Galán P, Wiestner A.

Leukemia · research support, n.i.h., intramural; research-article; journal article · DOI 10.1038/leu.2013.131

Bibliografisk träff 2013-03-01

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Brown JR.

Curr Hematol Malig Rep · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1007/s11899-012-0147-9

Bibliografisk träff 2013-01-30

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.

Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S.

Br J Haematol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/bjh.12206

Bibliografisk träff 2012-10-08

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH.

J Clin Oncol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1200/jco.2012.42.7906

Bibliografisk träff 2012-09-11

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.

Cell Signal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.cellsig.2012.09.008

Bibliografisk träff 2011-12-16

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA.

Blood · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/blood-2011-10-386417